Strong Revenue Growth
Total revenue reached $354.7 million, showing a year-over-year growth of 17.8% on a reported basis and 16.9% in constant currency. U.S. revenue grew by 21.5% to $275 million.
VTE Franchise Leading Growth
The VTE franchise delivered a 34% year-over-year growth, driving overall corporate growth.
Embolization and Access Revenue Surge
U.S. embolization and access revenue increased by 29.2% year-over-year to $83 million.
Gross Margin Expansion
Gross margin improved to 67.8%, up 130 basis points from the previous year, with expectations to reach over 70% by the end of 2026.
Positive Feedback for STORM-PE Trial
STORM-PE trial results showed CAVT superior in reducing right heart strain in PE patients with a favorable safety profile, receiving positive feedback from the medical community.
Raising Revenue Guidance
The company raised its revenue guidance for the year to $1.375 billion to $1.380 billion.